{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Alivus Life Sciences Ltd
Alivus Life Sciences Technical Momentum Shifts Amid Mixed Market Signals
Alivus Life Sciences, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, reflecting a complex interplay of market forces. Recent evaluation adjustments reveal a transition from a bearish to a mildly bearish trend, underscoring nuanced changes in price dynamics and technical indicators that investors should carefully consider.
Alivus Life Sees Revision in Market Assessment Amidst Sector Challenges
Alivus Life, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent performance trends and sector dynamics. The company’s assessment metrics have been adjusted following a period of subdued financial growth and technical indicators signalling caution.
Why is Alivus Life falling/rising?
As of 24-Nov, Alivus Life Sciences Ltd shares have declined by 0.75% to ₹897.25, continuing a downward trend influenced by underwhelming financial performance and subdued investor participation despite the company’s strong management efficiency.
Alivus Life Sciences Faces Bearish Momentum Amid Mixed Technical Signals
Alivus Life Sciences, a key player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a shift in price momentum with technical indicators signalling a predominantly bearish trend. Recent market data reveals a nuanced picture of the stock’s performance, highlighting challenges amid broader sector dynamics and market conditions.
Is Alivus Life technically bullish or bearish?
As of November 17, 2025, the trend is mildly bearish, supported by bearish momentum from the weekly MACD and daily moving averages, while monthly indicators present a mixed outlook with some mild bullish signals.
Alivus Life Sciences Faces Technical Trend Shifts Amid Market Evaluation Revision
Alivus Life Sciences, a small-cap in the Pharmaceuticals and Biotechnology sector, has recently revised its evaluation amid market dynamics. The stock has shown resilience over three years with a significant return, although its one-year performance contrasts with the Sensex. Ongoing performance monitoring remains crucial in this competitive landscape.
Why is Alivus Life falling/rising?
As of 17-Nov, Alivus Life Sciences Ltd is seeing a price increase to 945.40, up 4.54%, but has underperformed over the past year with a return of -11.99%. Despite recent gains and strong management efficiency, long-term growth prospects are weak, and the stock is trading at a premium compared to peers.
Is Alivus Life technically bullish or bearish?
As of November 13, 2025, the market trend has shifted to a moderately strong bearish stance, driven by bearish signals from the weekly MACD, Bollinger Bands, and daily moving averages, despite some mild bullishness indicated by the KST.
Alivus Life Sciences Faces Technical Trend Adjustments Amid Market Challenges
Alivus Life Sciences, a small-cap in the Pharmaceuticals and Biotechnology sector, is experiencing a technical trend adjustment with a current price of 903.25. Despite a challenging year with a -14.86% return, the company has shown resilience over three years, achieving a 112.01% return, outperforming the Sensex.
Is Alivus Life technically bullish or bearish?
As of November 10, 2025, Alivus Life's trend is mildly bearish, with bearish momentum indicated by the weekly MACD and daily moving averages, despite some mildly bullish signals from the weekly KST.
Alivus Life Sciences Faces Mixed Technical Trends Amid Market Evaluation Revision
Alivus Life Sciences, a small-cap in the Pharmaceuticals and Biotechnology sector, has recently revised its evaluation amid market challenges. Despite a negative annual return, the company has shown resilience over three years, significantly outperforming the Sensex. Technical indicators present a mixed outlook, reflecting current market dynamics.
Are Alivus Life latest results good or bad?
Alivus Life Sciences' latest Q2 FY26 results show a decline in net sales and net profit, indicating operational challenges, though year-on-year growth remains positive. The company is debt-free and maintains strong return metrics, but recent performance volatility raises concerns about future profitability.
Why is Alivus Life falling/rising?
As of 06-Nov, Alivus Life Sciences Ltd is priced at 893.85, down 1.3% and underperforming its sector and the market over various time frames. Despite strong management efficiency, the stock has shown poor long-term growth and is trading below key moving averages, contributing to a lack of investor confidence.
How has been the historical performance of Alivus Life?
Alivus Life has shown consistent growth over the past six years, with net sales increasing from 1,537.31 Cr in March 2020 to 2,386.88 Cr in March 2025, and profit after tax rising from 313.10 Cr to 485.63 Cr. Total assets also grew significantly from 1,725.60 Cr to 3,411.45 Cr, reflecting a strong expansion strategy.
Alivus Life Sciences Q2 FY26: Margin Pressures Persist Amid Sequential Revenue Decline
Alivus Life Sciences Ltd., a small-cap pharmaceutical company with a market capitalisation of ₹11,012 crores, reported a sequential decline in its Q2 FY26 performance, raising concerns about near-term momentum. Net profit for the quarter stood at ₹121.54 crores, declining 14.32% quarter-on-quarter from ₹141.87 crores in Q1 FY26, though registering a modest 9.02% year-on-year growth from ₹111.48 crores in Q2 FY25. The stock has faced sustained selling pressure, declining 18.67% over the past year and trading at ₹893.85 as of November 6, 2025, down 29.05% from its 52-week high of ₹1,259.75.
Is Alivus Life technically bullish or bearish?
As of 13 October 2025, Alivus Life's technical trend is bearish with moderate strength, indicated by a bearish MACD, moving averages, and Bollinger Bands, while the KST shows mixed signals between weekly and monthly timeframes.
Alivus Life Sciences Faces Bearish Technical Trends Amid Market Volatility
Alivus Life Sciences, a small-cap pharmaceutical company, has experienced a decline in stock price and performance over the past year, contrasting with the Sensex's modest gain. Despite recent challenges, the company has shown resilience with significant long-term returns, indicating potential volatility in its market dynamics.
Is Alivus Life technically bullish or bearish?
As of October 9, 2025, the market trend is mildly bearish, with mixed signals from indicators suggesting a cautious outlook, particularly in the short term.
Alivus Life Sciences Faces Mixed Technical Trends Amid Market Evaluation Revision
Alivus Life Sciences, a small-cap pharmaceutical company, has seen a slight stock price increase amid a challenging year, marked by a 20.9% decline. Technical indicators present a mixed outlook, while the company has significantly outperformed the Sensex over three years, showcasing resilience despite recent difficulties.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
